Stock AWKN AWAKN LIFE SCIENCES CORP.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Awakn Life Sciences Corp.

Equities

AWKN

CA05455W1086

Biotechnology & Medical Research

Market Closed - Canadian Securities Exchange
Other stock markets
 02:27:53 2024-04-29 pm EDT 		5-day change 1st Jan Change
0.175 CAD -20.45% Intraday chart for Awakn Life Sciences Corp. -2.78% +20.69%
Apr. 03 Awakn Life Sciences Corp. Announces Launch of Licensing Partnership Agreement with Rivus Wellness and Research Institute CI
Apr. 03 Awakn Life Sciences Corp. announced that it expects to receive CAD 1 million in funding CI

Valuation

Fiscal Period: January 2022 2023
Capitalization 1 50.77 10.88
Enterprise Value (EV) 1 50.96 12.62
P/E ratio -2.81 x -0.92 x
Yield - -
Capitalization / Revenue 215,093,845 x 7,275,603 x
EV / Revenue 215,880,506 x 8,442,474 x
EV / EBITDA -5.24 x -1.44 x
EV / FCF -8,799,368 x -3,053,399 x
FCF Yield -0% -0%
Price to Book 14.9 x 12.8 x
Nbr of stocks (in thousands) 24,887 32,476
Reference price 2 2.040 0.3350
Announcement Date 4/28/22 4/27/23
1CAD in Million2CAD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: January 2021 2022 2023
Net sales - 0.236 1.495
EBITDA 1 -0.8402 -9.733 -8.795
EBIT 1 -0.8403 -9.794 -9.192
Operating Margin - -4,149.34% -614.69%
Earnings before Tax (EBT) 1 -1.475 -16.47 -9.652
Net income 1 -1.475 -15.95 -9.143
Net margin - -6,755.65% -611.4%
EPS 2 -0.1168 -0.7261 -0.3628
Free Cash Flow - -5.791 -4.135
FCF margin - -2,453.36% -276.49%
FCF Conversion (EBITDA) - - -
FCF Conversion (Net income) - - -
Dividend per Share - - -
Announcement Date 5/21/21 4/28/22 4/27/23
1CAD in Million2CAD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: January 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2
Net sales - 0.2043 0.2532 0.3399 0.4305 0.4718 0.5108 -
EBITDA 1 - -3.548 -2.508 -2.012 -1.658 -1.981 -1.78 -1.459
EBIT 1 - -3.956 -2.647 -2.308 -1.883 -2.354 -1.951 -1.463
Operating Margin - -1,936.52% -1,045.54% -679.13% -437.3% -498.97% -381.96% -
Earnings before Tax (EBT) 1 - -4.178 -2.801 -2.388 -1.623 -2.839 -1.68 -1.151
Net income 1 -2.946 -4.041 -2.717 -2.299 -1.471 -2.655 -1.68 -1.75
Net margin - -1,977.74% -1,073.35% -676.51% -341.68% -562.77% -328.95% -
EPS 2 - -0.1600 -0.1100 -0.0900 -0.0500 -0.0900 -0.0600 -0.0600
Dividend per Share - - - - - - - -
Announcement Date 12/15/21 4/28/22 6/14/22 9/14/22 12/15/22 4/27/23 6/14/23 9/14/23
1CAD in Million2CAD
Estimates

Balance Sheet Analysis

Fiscal Period: January 2021 2022 2023
Net Debt 1 - 0.19 1.74
Net Cash position 1 0.23 - -
Leverage (Debt/EBITDA) - -0.0191 x -0.1984 x
Free Cash Flow - -5.79 -4.13
ROE (net income / shareholders' equity) - -945% -649%
ROA (Net income/ Total Assets) - -159% -102%
Assets 1 - 10.03 8.968
Book Value Per Share 2 0.0200 0.1400 0.0300
Cash Flow per Share 2 0.0200 0.0700 0.0200
Capex 1 0.27 1.7 0.1
Capex / Sales - 721.09% 6.38%
Announcement Date 5/21/21 4/28/22 4/27/23
1CAD in Million2CAD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
AWAKN LIFE SCIENCES CORP. Stock Awakn Life Sciences Corp.
+20.69% 6.35M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.77% 42.75B
LONZA GROUP AG Stock Lonza Group AG
+47.70% 41.61B
MODERNA, INC. Stock Moderna, Inc.
+12.24% 41.34B
CELLTRION, INC. Stock Celltrion, Inc.
-8.83% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+7.44% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-23.01% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+30.56% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-1.82% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+8.35% 11B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. AWKN Stock
  4. Financials Awakn Life Sciences Corp.